With Bristol Myers in its sights, Pfizer declares itself the winner in the S1P drug race to come — but you’ll have to wait for proof
From the moment Pfizer plunked down close to $7 billion to buy Arena and jump into one of the hottest games in the industry …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
